Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Can personalized medicine live up to its hype in health care?

Ketan Desai, MD, PhD
Meds
February 18, 2023
Share
Tweet
Share

The genius of Henry Ford was in his perfection of mass production. Ford’s assembly lines produced oodles of Model T, with economies of scale so that the cost of each car fell to the point that even those working in those lines could afford them. His method was copied by other car manufacturers and ultimately by other industries as well.

The pharmaceutical industry was one of them. The industry mass produces medicines with the same dose, frequency, and strength, irrespective of the patient’s ethnicity, body weight, height, or gender. This assembly line keeps the cost of medicines below what they could have been (though Americans do pay a lot more than citizens of other countries, mainly due to marketing tactics). It is largely due to the pharmaceutical industry that the longevity of humans has increased exponentially over the past century. And, in turn, has made the pharma/biotech sector among the most profitable.

However, a wrinkle has shown up. Most low-hanging fruits that synthetic chemistry could conjure have been picked. The industry has moved to biologics, which are more expensive to make. Nevertheless, they can still stick to the Model T paradigm. But, since science is restless, the boundaries are being pushed, and the concept of personalized medicine is now being increasingly touted.

Perhaps CAR T therapy best exemplifies personalized medicine. It is now routinely being proposed for cancers and even auto-immune diseases like lupus. Chimeric antigen receptor (CAR) T-cell therapy is a way to get immune cells called T cells (a type of white blood cell) to fight cancer by changing them in the lab so they can find and destroy cancer cells. CAR T-cell therapy is also sometimes talked about as a type of cell-based gene therapy because it involves altering the genes inside T cells to help them attack cancer. As can be easily understood, this is individualized, taking 9 to 14 days per patient.

In principle, this would lead to better efficacy and safety as the drug is personalized to suit a patient’s genetic and phenotypic characteristics. At least, that is the theory, for it has not always been borne out, as GlaxoSmithKline discovered. In addition, it has a downside in that being personalized; it cannot be mass-produced. Therefore, it is very expensive, costing up to $1 million per patient (including the follow-up). And that is a big problem. For example, treating 250,000 lupus patients in the U.S. would cost $25 billion. For only one disease.

To put that in perspective, let us appreciate that America spends approximately 20 percent of its GDP on health care. A large part of that is the cost of drugs, especially biologics. That is more than twice the OECD average. The pushback against excessive health care spending has already started, and laws have been passed restricting the price of drugs. In a couple of years, Medicare will be able to negotiate the price of drugs. It will start with a few drugs and then expand. And where Medicare goes, so will other insurance companies.   This will severely curtail the ability of pharma/biotech companies to continue charging a premium in the U.S. If pharma/biotech companies cannot charge a high price for personalized medicine drugs, they will have little incentive to develop or market them.   And without commensurate payment, physicians will not be able to prescribe them.

The other problem with personalized medicine is the time it takes to make them. Unlike an assembly line, each “medicine” is made much like an expensive, custom-fitted Italian suit. No more than 2,000 procedures can be done in the whole of U.S. To accommodate all Americans, every single hospital bed will have to be converted the CAR T therapy, which is impossible. Thus from a logistical point of view, it is impractical to consider personalized medicine as a potential pathway.

With these considerations, health care authorities and decision-makers should look at personalized medicine carefully and pragmatically and not be vowed by science. Ultimately, someone will have to foot the bill. And the newly-minted Republican congress is in no mood to oblige.

Ketan Desai is a physician executive.

Prev

Assess your tech health in 2023: How screen use is affecting your life and ways to improve

February 18, 2023 Kevin 0
…
Next

Why patients choose who they trust: Understanding the psychology of health care relationships

February 18, 2023 Kevin 0
…

Tagged as: Oncology/Hematology

Post navigation

< Previous Post
Assess your tech health in 2023: How screen use is affecting your life and ways to improve
Next Post >
Why patients choose who they trust: Understanding the psychology of health care relationships

ADVERTISEMENT

More by Ketan Desai, MD, PhD

  • Biological weapons: a history and emerging risks

    Ketan Desai, MD, PhD
  • The dark side of immortality: What if we could live forever?

    Ketan Desai, MD, PhD

Related Posts

  • How social media can help or hurt your health care career

    Health eCareers
  • Family medicine and the fight for the soul of health care

    Timothy Hoff, PhD
  • How the health care system fails to match its hype

    Robert Pearl, MD
  • Health care is not a service commodity

    Peter Spence, MD, MBA
  • Is medicine right for you? Exploring the benefits and challenges of a health care career.

    Timothy Dillinger
  • Practicing great medicine got a lot simpler. It’s health care that’s getting in the way.

    Paula Muto, MD

More in Meds

  • FDA delays could end vital treatment for rare disease patients

    GJ van Londen, MD
  • Pharmacists are key to expanding Medicaid access to digital therapeutics

    Amanda Matter
  • How medicine repurposing enables value-based pain management and insomnia therapy

    Olumuyiwa Bamgbade, MD
  • Forced voicemail and diagnosis codes are endangering patient access to medications

    Arthur Lazarus, MD, MBA
  • From stigma to science: Rethinking the U.S. drug scheduling system

    Artin Asadipooya
  • How drugmakers manipulate your health from diagnosis to prescription

    Martha Rosenberg
  • Most Popular

  • Past Week

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • America’s ER crisis: Why the system is collapsing from within

      Kristen Cline, BSN, RN | Conditions
    • Why timing, not surgery, determines patient survival

      Michael Karch, MD | Conditions
    • How early meetings and after-hours events penalize physician-mothers

      Samira Jeimy, MD, PhD and Menaka Pai, MD | Physician
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
  • Recent Posts

    • Why the heart of medicine is more than science

      Ryan Nadelson, MD | Physician
    • How Ukrainian doctors kept diabetes care alive during the war

      Dr. Daryna Bahriy | Physician
    • Why Grok 4 could be the next leap for HIPAA-compliant clinical AI

      Harvey Castro, MD, MBA | Tech
    • How women physicians can go from burnout to thriving

      Diane W. Shannon, MD, MPH | Physician
    • What a childhood stroke taught me about the future of neurosurgery and the promise of vagus nerve stimulation

      William J. Bannon IV | Conditions
    • Beyond burnout: Understanding the triangle of exhaustion [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

Leave a Comment

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • America’s ER crisis: Why the system is collapsing from within

      Kristen Cline, BSN, RN | Conditions
    • Why timing, not surgery, determines patient survival

      Michael Karch, MD | Conditions
    • How early meetings and after-hours events penalize physician-mothers

      Samira Jeimy, MD, PhD and Menaka Pai, MD | Physician
  • Past 6 Months

    • Forced voicemail and diagnosis codes are endangering patient access to medications

      Arthur Lazarus, MD, MBA | Meds
    • How President Biden’s cognitive health shapes political and legal trust

      Muhamad Aly Rifai, MD | Conditions
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • The One Big Beautiful Bill and the fragile heart of rural health care

      Holland Haynie, MD | Policy
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
  • Recent Posts

    • Why the heart of medicine is more than science

      Ryan Nadelson, MD | Physician
    • How Ukrainian doctors kept diabetes care alive during the war

      Dr. Daryna Bahriy | Physician
    • Why Grok 4 could be the next leap for HIPAA-compliant clinical AI

      Harvey Castro, MD, MBA | Tech
    • How women physicians can go from burnout to thriving

      Diane W. Shannon, MD, MPH | Physician
    • What a childhood stroke taught me about the future of neurosurgery and the promise of vagus nerve stimulation

      William J. Bannon IV | Conditions
    • Beyond burnout: Understanding the triangle of exhaustion [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Leave a Comment

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...